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ABSTRACT
Expression of the tumour suppressor Deleted in Colorectal Cancer (DCC) and the related protein
neogenin is reduced by the mammalian serine protease chymotrypsin or the bacterial serine protease
subtilisin, with increased cell migration. The present work examines whether these actions are asso-
ciated with changes in the expression of cadherins, β-catenin and vimentin, established markers of the
Epithelial-Mesenchymal Transition (EMT) which has been linked with cell migration and tumour metas-
tasis. The results confirm the depletion of DCC and neogenin and show that chymotrypsin and subtilisin
also reduce expression of β-catenin in acutely prepared tissue sections but not in human mammary
adenocarcinoma MCF-7 or MDA-MB-231 cells cultured in normal media, or primary normal human
breast cells. A loss of β-catenin was also seen in low serum media but transfecting cells with a dcc-
containing plasmid induced resistance. E-cadherin was not consistently affected but vimentin was
induced by low serum-containing media and was increased by serine proteases in MCF-7 and MDA-
MB-231 cells in parallel with increased wound closure. Vimentin might contribute to the promotion of
cell migration. The results suggest that changes in EMT proteins depend on the cells or tissues
concerned and do not parallel the expression of DCC and neogenin. The increased cell migration
induced by serine proteases is not consistently associated with the expression of the EMT proteins
implying either that the increased migration may be independent of EMT or supporting the view that
EMT is not itself consistently related to migration. (241).
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Introduction
The tumour suppressor protein Deleted in Colorectal Cancer
(DCC) has been linked with a variety of cancer cells fromwhich
it is either absent or in which its concentration or activity is
substantially below that in non-cancerous tissues.1–5 Its loss or
dysfunction by genetic, epi-genetic or acute disruption may
represent one of the several factors required for a normal cell
to undergo transformation into a cancerous cell.6 We have
recently reported that the cellular expression of DCC, as well
as the structurally and functionally related molecule neogenin-
7–9 both of which are receptors for the secreted family of netrin
proteins10 can be depleted by the mammalian serine protease
chymotrypsin, which is present in the gastro-intestinal tract
and systemic circulation, and by the bacterial chymotryptic
enzyme subtilisin.11,12 The removal of DCC and neogenin
was accompanied by increased motility and migration in sev-
eral transformed cell lines including human neuroblastoma
(SH-SY5Y) cells and the mammary adenocarcinoma lines
MCF-7 and MDA-MB-231. Since chymotrypsin levels in the
intestine and circulation are increased with obesity, and since
subtilisin is present in processed meat products and agricul-
tural probiotics, it was suggested that these effects might con-
tribute to the associations between a meat-based diet, obesity
and carcinogenesis.11–13 The effects of chymotrypsin and sub-
tilisin were prevented by Bowman-Birk inhibitors found in
many fruit and vegetables, consistent with the hypothesis that
a plant-rich diet would be protective against cancer11,12 as
concluded by several recent epidemiological studies.14,15
The present work probes further into the interactions
between DCC and serine proteases by assessing their effects on
markers of Epithelial-Mesenchymal Transition (EMT).
E-cadherin is central to the formation of adherens junctions
between cells and its presence reflects the existence of a stable,
resting colony of cells. E-cadherin is a key regulator of EMT
initiation and its expression falls as cells lose adherence and
adopt a more aggressive, motile phenotype associated with the
EMT phase of migration and the formation of distant
metastases.16–21 β-catenin normally exists in association with
E-cadherin in junctional complexes so that a fall in E-cadherin
expression results in an increase in unbound β-catenin levels in
the cytoplasm from where it can enter the nucleus and can – as a
component of the wingless (Wnt) transduction system – activate
transcription factors that promote increased proliferation and
cell migration.22–32 Any β-catenin which is phosphorylated in
the cytoplasm remains trapped there until it is transported to the
proteasome for degradation and disposal.25,33,34 Small molecule
inhibitors of β-catenin are able to suppress carcinogenesis.35
Vimentin is a microtubular component involved in the
regulation of cytoskeletal function relevant to the changes in
intercellular adhesion and EMT.36–39 The expression of
vimentin is increased as cells lose adherence and transition
from a resting, epithelial phenotype to a migratory behaviour.
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These aspects of E-cadherin, β-catenin and vimentin func-
tion have resulted in their being linked to a range of cancers,
with a fall in E-cadherin levels and increased free β-catenin
and vimentin concentrations viewed as characteristic of early
malignancy, whereas N-cadherin expression – where it occurs
– declines. If this relationship is valid, we predicted that the
increased cell migration induced by serine proteases should be
accompanied by a reduction in E-cadherin expression and
increased β-catenin and vimentin. The objectives of the
study were firstly to examine the effects of chymotrypsin
and subtilisin on the expression of these proteins to assess
whether any effects could contribute to the functional changes
in cell behaviour.11 A second objective was to generate cells
possessing exogenous, transfected DCC to determine whether
this would modify the expression of EMT markers and, if so,
whether they would be susceptible to change by chymotrypsin
and subtilisin.
An additional reason for clarifying the relationships
between the tumour suppressors and EMT markers is that
the widely accepted view of EMT as being fundamental to cell
migration and metastasis has been challenged by studies
which indicate a greater role in determining cell susceptibility
to toxic factors including chemotherapeutic drugs.40 The
results may, therefore, be relevant to treating cancer resistance
to chemotherapy and the development of drugs which are less
likely to induce or encounter resistance.
Materials and methods
Since we have found that the commonly used housekeeping
genes such as actin can be affected by the serine proteases, we
have used the cytoskeletal protein RhoA in most cases as a
control for consistency of protein content and immunoblot-
ting efficiency.11 This protein is unaffected by serine proteases
at concentrations which affect the proteins of primary interest
in this study.
Tissue slices
As in our previous work initial experiments were performed
on normal mature adult tissue using 450 μm thick sections of
adult rat hippocampus which can be maintained for several
hours in a simple, oxygenated physiological solution of
defined composition analogous to natural cerebrospinal fluid
(CSF) and without the need for serum or other additives,
conditions under which they exhibit physiologically normal
electrical activity and neuronal communication. These slices
are exactly similar to those used routinely for the electrophy-
siological recording of synaptic potentials and which have
been used to compare the physiological and molecular effects
of various compounds.
Male Wistar rats (sourced from Harlan Olac, UK)
between 100-150 g in weight (4–8 weeks old) were term-
inally anaesthetised with a 25% aqueous solution of
urethane (5 ml/kg) and then killed by cervical dislocation.
The brain was rapidly removed into ice-cold artificial CSF
of composition (in mM): NaCl 115; KH2PO4 2.2; KCl 2;
MgSO4 1.2; NaHCO3 25; CaCl2 2.5; glucose 10, gassed
with 5%CO2 in air. The hippocampi were rapidly dissected
out and chopped into 450 μm transverse slices using a
McIlwain tissue chopper. The slices were held in ice-cold
artificial CSF and transferred to mini-petri dishes (dia-
meter 35 mm) in an incubation chamber where they
were maintained in the water-saturated atmosphere of
5%CO2 in air at room temperature (~ 20°C). After a
recovery period of 1-2 h, compounds were added to the
slices for 4 h, at which time the solution was withdrawn by
pipette and replaced by fresh, drug-free solution. This
replenishment was repeated twice more until, after 45 min-
utes, individual slices were washed in fresh solution and
transferred to Eppendorf tubes pre-cooled to −20°C in dry
ice and stored at −80°C until used for immunoblotting.
Immunoblotting
Hippocampal slices were homogenised in RIPA buffer (50 mM
Tris, 150 mMNaCl, 0.1% SDS, 0.5% Triton X-100, 1% IGEPAL,
with a Roche complete protease inhibitor tablet) and centrifuged
at 15000 g for 5 min at 4°C. Cell cultures were briefly washed in
ice cold PBS, scraped in ice cold RIPA buffer and the cell
suspension centrifuged at 15000 g for 5 min at 4°C.
Supernatants from tissue and cells were collected for protein
concentration determination using the Bio-Rad protein assay
(Bio-Rad, Hemel Hempstead, UK). Samples were normalised
to 10 μg and prepared as follows: 65% protein sample, 25%
sample buffer and 10% reducing agent (Life Technologies,
Paisley, UK) and heated at 70°C for 10 min. The protein samples
were loaded onto NuPAGENovex 4–12% Bis-Tris (1 mM) 15 or
17 lane gels (Life Technologies, Paisley, UK) and run at 175 volts
for 70 min to separate proteins according to their molecular
weight. SeeBlue pre-stained standard (10 μL)(Life
Technologies, Paisley, UK) was included on each gel as a mole-
cular weight marker. The separated proteins were then blotted
onto Invitrolon polyvinylidene difluoride) membranes (Life
Technologies, Paisley, UK) at 35 V for 70 min. After rinsing
well with distilled water, membranes were blocked for 1 h in 5%
non-fat dried milk solution in Tris-buffered saline containing
0.05% Tween (TBST) before overnight incubation at 4°C with
the appropriate primary antibody (diluted in 5% milk-TBST).
Membranes were thenwashed 3 times for 15min with TBST and
incubated with the appropriate horseradish peroxidase (HRP)
conjugated secondary antibody (prepared in 5% milk-TBST) for
1 h at room temperature. Following secondary antibody incuba-
tion, blots were washed 3 times for 15 min with TBST then
visualised using a Pierce Enhanced Chemiluminescence 2 detec-
tion kit (Fisher Scientific, Loughborough, UK).
Western blot analysis was carried out using the following
primary antibodies:-
From Santa Cruz, Insight Biotechnology, Wembley, UK:-
Neogenin (goat polyclonal, sc-6536, 1:1000); E-cadherin (mouse
monoclonal, sc-8426, 1:1000 dilution); N-cadherin (mousemono-
clonal, sc-271386; 1:1000 dilution); pan-cadherin (mouse mono-
clonal, sc-59876; 1:1000 dilution); vimentin (mouse monoclonal,
sc-7557, 1:1000 dilution); RhoA (mouse monoclonal, sc-418,
1:5000 dilution); β3-tubulin (mouse monoclonal, sc-51670,
1:1000 dilution);
From BD Pharmingen, Oxford, UK):- DCC (mouse mono-
clonal, 554223, 1:5000 dilution);
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From Abcam, Cambridge, UK):- β-catenin (rabbit mono-
clonal, ab32572, 1:5000 dilution).
The following secondary HRP-conjugated antibodies were
used at a 1:5000 dilution: donkey anti-goat HRP (sc-2020);
goat anti-mouse (sc-2005); donkey anti-rabbit HRP (sc-2313)
(from Santa Cruz, Insight Biotechnology, Wembley, UK).
Data analysis
All Western blots were quantified using the Image J software
and comparisons were made statistically between groups of
slices or cultures using ANOVA followed by the Bonferroni
post hoc multiple comparison test for selected datasets. The
analyses were performed with Instat 3.0 software (GraphPad,
San Diego, USA). A probability value of 0.05 was adopted as
the criterion for significance. Actual P-values are indicated
when provided by the Instat software.
Immunocytochemistry
Cells were passaged into 24-well plates containing poly
D-lysine (50 µg/ml, Sigma Aldrich, UK; product P7280)
coated glass coverslips. Following individual experimental
protocols, cells were fixed with 500 µl of 4% paraformalde-
hyde (PFA) for 30 minutes at 4°C and were then rinsed 3
times for 3 min with PBS before being incubated overnight
at 4°C in primary antibody made up in PBS with 0.3%
Triton X (250 μl per well). The following day, after 3 × 3 min-
ute PBS rinses, cells were incubated in the appropriate
secondary fluorescent antibody at 1:200 dilution in PBS
with 0.3% Triton X (250 μl per well) for 1 hr at room
temperature. This was followed by 3 × 3 minute PBS rinses
before mounting the coverslips with Vectashield® fluores-
cent mounting medium (Vector Laboratories, California;
product H-1000) on microscope slides where they were
sealed and subsequently stored at −20°C prior to image
analysis.
Primary antibodies were as noted under Western blots,
used at dilutions of: DCC 1:500; neogenin 1:500; β-catenin
1:1000. Secondary antibodies were obtained from Molecular
Probes, Life Technologies, Paisley, UK; AlexaFluor 488 goat
anti-rabbit #A11008; used at 1:200 dilution.
Cell cultures
The MCF-7 cell line is an adherent, human Caucasian breast
adenocarcinoma cell line purchased at passage 15 (ECACC,
Wiltshire, UK. #86012803). We routinely used this cell line
only in the first 30 passages following resuscitation. The
medium used consisted of Minimum Essential Medium
Eagle (EMEM): 2 mM glutamine; 1% penicillin/streptomycin;
1% Non-Essential Amino Acids (NEAA) and 10% Fetal
Bovine Serum (FBS). The cells were maintained at 37°C in
5%CO2. Cells were plated at an initial density of 1 × 10
5 cells/
ml unless otherwise stated. This cell line was passaged once
per week and fed every 2–3 days by a 50% media exchange.
The MDA-MB-231 cell line is an adherent, human
Caucasian breast adenocarcinoma cell line purchased at pas-
sage 40 (ECACC, Wiltshire, UK, #92020424). This line was
used for a limited number of passages (not more than 30 from
initial passage number). The medium used was L15: 1% peni-
cillin/streptomycin, 2 mM glutamine and 15% FBS unless
otherwise indicated. The cells were maintained at 37°C in a
humidified CO2-free environment. Cells were plated at an
initial density of 1 × 105 cells/ml unless otherwise stated.
This cell line was passaged twice per week and fed every
2–3 days, when required, with a 50% media change.
The SH-SY5Y cell line (ECACC, Wiltshire, UK,
#94030304) is an adherent, human neuroblastoma cell line
obtained at a passage number of 17. This cell line was only
used up to passage 30 as beyond this passage the line begins to
lose its neuronal characteristics as measured by β-tubulin
protein expression using Western blot analysis. The medium
used for this cell line was HAM’s F-12: EMEM (1:1): 2 mM
glutamine, 1% penicillin/streptomycin, 1% NEAA and 15%
FBS (reduced to 10% once cultures were established) unless
otherwise indicated. The cells were maintained at 37°C in a
humidified atmosphere containing 5%CO2. Cells were plated
at an initial density of 5 × 104 cells/ml unless otherwise stated.
This cell line was passaged once per week and fed every
2–3 days with a 50% media change.
Normal adult human primary mammary epithelial cells
(HMEpC) (ECAC, Wiltshire, UK, #06090747; Cell
Applications #830-85 A) were obtained at 5th passage and
were maintained in culture for up to 16 doublings. The cells
were grown in Human Mammary Epithelial Cell Growth
Medium (Cell Applications #815–500, Sigma). This is a
defined medium which does not require serum supplementa-
tion. HMEpC were maintained at 37°C in 5% CO2. The
primary cells were passaged once per week and seeded at a
density of 5000 cells/cm2. Cultures were fed every 2–3 days
with a 50% media change. During passaging, the trypsin was
inactivated by adding media containing 10% FBS. The serum
was then removed by centrifuging and re-suspending the
pellet in serum free media complete growth medium.
All cell lines were passaged using a 0.25% trypsin-EDTA
solution (Sigma, T4049) added to the cells briefly before being
removed. Cells were then incubated at 37°C for 2–4 minutes
until all cells detached from the flask. The trypsin was then
neutralised by the addition of medium containing FBS. Again,
for the purposes of the primary cell line, following neutralisa-
tion, the cells were gently spun down and the medium con-
taining FBS was removed and cells re-suspended in HMEpC
medium before cell densities were calculated by counting on a
haemocytometer and appropriate dilution in media.
All media components were obtained from Sigma-Aldrich
UK, with product codes as follows: HAM’s F-12: N4888;
EMEM: #M2279; Human Mammary Epithelial Cell Growth
Medium (#815K-500); NEAA: M7145; L-glutamine: G7513;
Penicillin/Streptomycin: P0781; FBS: F9665.
Agarose spot migration
As a test of chemotactic migration we used the agarose spot
method described by Wiggins & Rappoport41 as in our pre-
vious work.11 Low melting point agarose (LMA) (Sigma-
Aldrich, Poole, UK, #A9045) was made up to a 0.5% solution
in Dulbecco’s PBS (DPBS) (Life Technologies, Paisley, UK,
product #14190–094) by boiling until fully dissolved. The
CANCER BIOLOGY & THERAPY 3
solution was then cooled to 40°C ready for use. Human
netrin-1 (R&D systems, Abingdon UK, product #1254-N4)
was added to the LMA solution at 1000 ng/ml. Control
LMA solution contained DPBS only. A spot of 10 μl of
LMA solution was pipetted carefully into the centre of each
well of a 12-well plate and allowed to set for at least 1 hour in
a refrigerator at 4°C.
Cells were passaged in full serum media and 1.5 ml of cell
suspension was pipetted into each well containing an LMA
spot. They were incubated at 37°C in 5% CO2 for 4 hours
when the medium was changed to a migrating medium con-
taining 0.1% serum with dissolved compounds to be added to
the cells. After 24 hours the wells were photographed at x4
magnification on an Olympus IX50 inverted microscope
attached to an Olympus DP50 camera, utilising Cell software
from Soft Imaging System (EMSIS GmbH, Munster,
Germany). In total, 6 images were taken per well, correspond-
ing roughly to 12, 2, 5, 6, 7 and 10 o’clock positions. A
minimum of 4 different experiments from 4 different passages
were used for each experiment.
Data analysis
Image analysis for the spot assay was carried out using Image
J software (http://rsb.info.nih.gov/ij/). Cells that had crossed
into the spot were counted, and the average number of cells
per spot was calculated per treatment.
Wound healing assay
For assessing spontaneous migration potential, the wound or
scratch healing assay was used.11,42,43 Cells were plated at a
density of 2 × 105 cells/ml in 6-well plates in normal media.
These plates were previously marked with a grid reference aid
by scoring lines 2 mm apart on the bottom of the plate. After
attaining confluence a scratch wound was made down the
centre of each well (perpendicular to the grid reference)
with a sterile 200 µl pipette tip. The cells were then washed
twice with 1 ml of medium after which the cells were replen-
ished fully with 10% serum medium . Photographs were taken
immediately at 0 h at 3 points along the wound using an
Olympus DP50 camera attached to an Olympus IX50 inverted
microscope and Cell software at x4 magnification (Soft
Imaging Systems, EMSIS GmbH, Munster, Germany). These
three points were identified using the grid reference allowing
the same three points to be imaged at subsequent time points.
Following the initial image at t = 0 drugs of interest were
added. Photographs were subsequently taken after 24 h, 48 h
and 72 h and wound closure was quantified by measuring
open wound area, using the T-scratch software.
Data analysis
The percentage difference of open wound area between 0 h
and the later time points was calculated and comparisons
between control and treated groups were made using t-tests
based on the results obtained using the T-scratch software.
The analyses were performed with Instat 3.0 software
(GraphPad, San Diego,USA). A probability value of 0.05 was
adopted as the criterion for significance. Actual P-values are
indicated when provided by the software.
Proliferation:bromodeoxyuridine (brdu)assay
Proliferation was assessed in the MCF-7 and MDA-MB-231
breast adenocarcinoma cell lines and in the primary
(HMEpC) breast cells using a colorimetric BrdU ELISA kit
(ab126556, Abcam, Cambridge, UK). Each assay was per-
formed in triplicate. MCF-7 cells were plated at a density of
2 × 105 cells/ml in 96-well plates and left to attach for
24 hours. The cells were then treated with subtilisin and
α-chymotrypsin for 2, 6 or 24 hours. BrdU reagent was
added to the cells at 2, 6 and 24 hours to evaluate prolifera-
tion. A series of wells on each plate were left untreated with
BrdU as a background reading. The cells were fixed and the
DNA denatured before assaying. Briefly, cells were washed,
incubated with detector antibody for 1 hour, washed again
and then incubated with peroxidase conjugate secondary anti-
body for 1 hour. Following a final wash step, cells were
incubated for 30 mins with TMB peroxidase substrate. Stop
solution was added to the wells and plates read in a micro-
plate reader (Opsys MR, Dynex Technologies, Worthing, UK)
at dual wavelengths of 450/550 nm. Proliferation was
expressed as the mean optical density of BrdU positively
labelled cells/BrdU negative cells.
Data analysis
Statistical analyses were performed with Instat 3.0 software
(GraphPad, San Diego, USA), with a probability of 0.05
adopted as the criterion for significance. Actual P-values are
indicated when provided by the Instat software.
Transfection of dcc plasmid
A pCMV dcc plasmid (#16459) was obtained from Addgene
courtesy of Dr. B. Vogelstein. This plasmid contains the
Cytomegalovirus (CMV) promoter, a strong constitutive pro-
moter, the dcc gene flanked by 2 XhoI restriction sites, a
polyadenylation signal (Poly A), Ampicillin resistance gene
and Neomycin (Neo) resistance gene.
DH5alpha E.coli cells containing the plasmid were grown
on agar plates containing 75 μg/ml ampicillin and the plates
were incubated overnight at 37°C. Individual colonies of bac-
teria were picked with a sterile loop and used to inoculate
6 ml aliquots of Luria-Bertani medium containing ampicillin
and grown overnight in a shaking incubator at 37°C and
180 rmp. An aliquot of bacterial culture containing plasmid
was frozen down in 15% glycerol stocks and stored at −80°C.
The remaining bacterial medium was used to extract pCMV
dcc plasmid DNA using Pure yield plasmid miniprep system
(A1223, Promega UK, Southampton, UK) following manufac-
turer’s instructions.
Stable transfection was performed in MCF-7 cells and
transient transfection in MDA-MB-231 cells passaged in nor-
mal media, 24 h prior to transfection. To promote the effi-
ciency of transfection, cells were plated at a density sufficient
to result in approximately 60–70% confluency 24 h after
passage. At this time, normal medium was removed from
each well and replaced with antibiotic free medium for
approximately 1 h. The transfection reagent Lipofectamine
2000 was used (Life Technologies, Paisley, UK, #11668–027)
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for successful transfection of the DCC plasmid according to
the manufacturer’s instructions using a ratio of 1:2 DNA:
Lipofectamine 2000. Briefly, DNA (1000 ng for MCF-7
cells, 1500 ng for MDA-MB231 cells) was combined with
Lipofectamine 2000 in the presence of Optimem (Life
Technologies, Paisley, UK product 31985–062), incubated at
room temperature for 15 minutes and then added dropwise to
each well containing cells in antibiotic-free medium (250 µl in
6-well plates). Approximately 4-5 h after the introduction of
DNA, medium was removed and replaced with medium con-
taining antibiotics and test agents as required.
To generate the stable MCF-7 cell line, 48 hours post
transfection, cells were trypsinised, diluted 1:2 and plated in
6 well plates with antibiotic G418 at a concentration of
300 μg/ml (determined from a previous kill curve) before
transfer to 24-well plates where the cells were fed every 3 to
4 days with G418 containing media. Islands of surviving cells
were isolated using cloning cylinders, where they were then
grown and collected for further use as a stable cell line.
Transfer of a single cell from these resistant colonies were
transferred to 96 well plates to confirm antibiotic resistance.
In experiments where MDA-MB-231 cells were only tran-
siently transfected with dcc, cells were either harvested for
Western blot analysis or used for further experiments 48 h
after the initial introduction of the plasmid.
Sources
From Sigma-Aldrich
Subtilisin A (#P3580); α-chymotrypsin (#C4129); chymostatin
(#C7268); Protease Inhibitor Cocktail (P2714); From Cayman
Chemicals: carfilzomib (#17554); Epoxomicin (#1000 7806);
From Tocris Chemicals: MG132 (#1748); R&D Systems:
Human recombinant netrin-1 (#6419-N1); hr-netrin-4
(#1254).
The protease inhibitor cocktail (PIC) provided AEBSF
hydrochloride 100 μM (inhibits serine proteases); aprotinin
15 nM (serine proteases and esterases); bestatin 6 μM (ami-
nopeptidases); E-64 50 nM (cysteine proteases); EDTA 50 μM
(metalloproteases); leupeptin 50 nM (cysteine and tryptic
proteases)
Results
Tissue slices
An acknowledged limitation of cell lines is that they are already
abnormal, so that an examination of factors that cause, or are
associated with, cancerous behaviour are based on cells which
may already have undergone changes in the signalling pathways
under investigation. As in our previous study11 we have therefore
attempted to circumvent this problem by using fresh tissue from
adult laboratory rats in addition to human cancer-derived and
human primary mammary cells. Brain sections were used as fresh
intact tissue since they retain higher concentrations of DCC in
adult rats than most other tissues and their use does not require
molecular manipulation before use: brain slices are prepared
acutely and used immediately in a simple chemically defined
medium (artificial cerebrospinal fluid, aCSF, seeMethods) lacking
added serum, enzymes or growth factors. Such slices retain most
of their biochemical and physiological properties for many hours
and are well established as a method of preserving physiological
levels of neuronal excitability and communication. The system
therefore provides a valuable means of comparing results with cell
cultures which, while being more amenable to molecular inter-
ference and being available for study over several days, need to be
maintained in relatively complex media with highly specific and
relatively artificial additions such as serum. This adds growth
factors and other nutritive components including trace elements
and undefined levels of endogenous enzymes and inhibitors
which are difficult to define absolutely.
As seen in Figure 1, the addition of chymotrypsin (CT,
1 µM) or subtilisin (sub, 100 nM) reduced the expression of
DCC (Figure 1A) and neogenin (Figure 1B) in tissue slices.
The concentrations used were based on our previous studies
of concentration-effect relationships.11 While both enzymes
are defined as chymotryptic in view of their overall substrate
specificity, the Protease Inhibitor Cocktail (PIC, see Methods
– Sources) – significantly inhibited only chymotrypsin and not
subtilisin (Figure 1A,B). The cytoskeletal protein RhoA was
unaffected at the same concentrations of the proteases
(Figure 1C), allowing its use as a housekeeping control for
protein loading as noted above.
Expression of β-catenin in the tissue was also reduced
significantly by chymotrypsin (Figure 1D) and subtilisin
(Figure 1E) and both these effects were blocked by PIC,
consistent with the loss of DCC and neogenin. In addition,
the effects of chymotrypsin and subtilisin on β-catenin expres-
sion were blocked by the highly selective serine protease
inhibitor chymostatin (Figure 1D,E) as we have shown pre-
viously for DCC and neogenin and confirming their substan-
tially similar chymotryptic substrate specificity.
Since β-catenin is normally ubiquitinylated and transported
to the proteasome for chymotryptic degradation, it was of inter-
est to determine whether the loss of β-catenin produced by
chymotrypsin was mediated through the chymotryptic activity
of the proteasome. This seems not to be the case since the
selective 20S proteasome inhibitors carfilzomib (50 nM), epox-
omicin (1 μM) and MG132 (10 μM) did not modify the activity
of chymotrypsin on β-catenin expression (Figure 1F), producing
a similar pattern to that reported previously for DCC and
neogenin.11 However, all three inhibitors showed a clear ten-
dency to increase the resting levels of β-catenin, the effect of
MG132 being statistically significant, consistent with a contin-
uous ongoing removal of β-catenin by proteasomal activity and
consistent with similar observations on DCC and neogenin in
earlier work.11 A pan-cadherin antibody indicated no overall
effect of chymotrypsin or the proteasome inhibitors on total
cadherin expression (Figure 1G) but in subsequent experiments
E-cadherin and N-cadherin were examined separately.
Cell cultures
MCF-7 mammary cancer cells
In the MCF-7 line of human mammary adenocarcinoma cells,
normal resting cells expressed neogenin but not DCC. In
normal 10% serum-containing medium, 48 h treatment with
chymotrypsin (CT 1000 nM) or subtilisin (sub 30, 100 nM)
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reduced the expression of neogenin (Figure 2A), with no effect
on RhoA (Figure 2B) at the same concentrations. When
the concentration of serum in the incubation medium was
reduced from 10% to 1% to reduce interference from serum
components the cells exhibited increased sensitivity to the
proteases such that chymotrypsin, even at 300 nM significantly
reduced neogenin expression and subtilisin at 100 nM comple-
tely eliminated neogenin expression (Figure 2C). There was
Figure 1. Effects of serine proteases on dependence receptor expression in tissue.
Bar charts showing the quantified Western blot densities of proteins expressed in rat brain slices. The charts indicate expression in normal tissue (con), or after 4 h
incubation with chymotrypsin (CT) 1 μM or subtilisin (sub) 100 nM alone or with the Protein Inhibitor Cocktail (PIC). Expression is shown of (A) DCC, (B) neogenin, (C)
RhoA. Panels (D) and (E) summarise the expression of β-catenin, its suppression by CT 1 μM (D) or sub 100 nM (E) and the blockade of these enzymes by PIC and
chymostatin 30 μM (CS). (F) and (G) quantify the expression of β-catenin (F) and cadherins (G) showing the effects of CT 1 μM alone or in combination with
carfilzomib 50 nM (CAR), epoxomicin 1 μM (epox) or MG132 10 μM (MG).
*P < 0.05, **P < 0.01, ***P < 0.001 (n = 3 or 4; ANOVA and Bonferroni post hoc test for selected datasets.)
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Figure 2. Effects of serine proteases on dependence receptor expression in MCF-7 cells.
Bar charts showing the quantified Western blot densities of proteins expressed in MCF-7 cells. Expression is shown of (A) neogenin and (B) RhoA after incubation in
normal medium containing standard 10% FBS. (C) and (D) show expression after culturing in low serum (1%) medium. The charts indicate expression in control
normal cells (con), or after 48 h exposure to chymotrypsin (CT) 300 or 1000 nM, or subtilisin (sub) 30 or 100 nM. (E), (F). Micrographs of cultures after 48 h exposure
to CT 300 or 1000 nM, or subtilisin 30, 100 or 300 nM under control conditions (E; 10% FBS-containing medium) or low serum (F; 1%) medium. Scale bar 100 μm. (G)
immunocytochemical localisation of β-catenin primarily in the cell membrane, with some cells exhibiting β-catenin in the cytoplasm. (H)-(M) show bar charts of
quantified Western blot densities in 10% serum medium (H, J, L,) or low 1% serum media (I, K, M) for β-catenin (H, I), RhoA (I, K), vimentin (J, K) and E-cadherin (L, M).
The charts indicate expression in normal cells (con), or after exposure to chymotrypsin (CT) 300 or 1000 nM, or subtilisin (sub) 30 or 100 nM. Each chart is
accompanied by a sample blot. (N) illustrates Western blots for MCF-7 cells or tissue slices, revealing the presence of E-cadherin but not N-cadherin in MCF-7 cells
whereas both are clearly expressed in adult brain tissue. (O) summarises the rate of wound closure 24, 48 and 72 h after wounding cultures under normal (control)
conditions (dark columns) or in the presence of subtilisin 100 nM (light columns). (P) Measurement of MCF-7 proliferation rate using the bromodeoxyuridine
technique under control conditions (con) or in the presence of subtilisin (sub) 30 or 100 nM, or chymotrypsin (CT) 300 or 1000 nM. Results are shown after 2 h (black
columns), 6 h (light shading) or 24 h (heavy shading).
*P < 0.05, **P < 0.01, ***P < 0.001 (n = 3; ANOVA and Bonferroni post hoc test for selected datasets).
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also a significant reduction (p = 0.05) of RhoA (Figure 2D) at
100 nM subtilisin, indicating a degree of sensitivity of the
cytoskeleton under these low serum conditions, or an increased
susceptibility to toxicity induced by the lack of some serum
components. An examination of cell morphology showed that,
in 10% serum-containing medium, the cells retained their
normal planar cohesive morphology in controls and low pro-
tease concentrations (Figure 2E,a–d). At 100 nM subtilisin the
cells began to reveal signs of disruption (Figure 2E,e) and at
300 nM this progressed to an obvious loss of adherence with
the formation of islands of cells which appeared to be seriously
damaged or dead (Figure 2E,f. Under the low serum (1%)
conditions (Figure 2F), the cells showed clear signs of disrup-
tion and death in chymotrypsin at 1 μM (Figure 2F,c) or
subtilisin 100 nM (Figure 2F,e).
β-catenin was clearly present primarily in the cell mem-
brane region of the MCF-7 cells (Figure 2G). The serine
proteases did not affect the expression of β-catenin or RhoA
in normal medium (Figure 2H) but in 1% media serum β-
catenin was reduced by 100 nM subtilisin (Figure 2I) possibly
indicating non-specific damage related to their combination
with the deficiency in serum components.
No significant vimentin expression was seen in MCF-7
cells cultured in normal 10% serum medium (Figure 2J), an
observation that has been made previously.44 There was, how-
ever, a suggestion (not significant) of expression in the pre-
sence of subtilisin (Figure 2J). This trend became highly
significant during incubation in 1% serum medium which
induced a clear baseline expression of vimentin (Figure 2K)
which was further increased by chymotrypsin (300 nM) and
the low (30 nM) concentration of subtilisin.
E-cadherin showed no significant loss of expression after
incubation with chymotrypsin or subtilisin in normal medium
(Figure 2L) but a clear tendency for a reduction by chymo-
trypsin at 1 μM and a significant reduction at 100 nM sub-
tilisin in low serum conditions (Figure 2M). Although
E-cadherin was present in MCF-7 cells, N-cadherin was not
detected. This could not be attributed to antibody failure as
tissue slices exhibited clear expression of both proteins
(Figure 2N).
Using the wound closure assay of spontaneous cell migra-
tion subtilisin at 100 nM (in 10% serum medium) increased
the amount of migration after 48 or 72 h, confirming that a
more aggressively motile phenotype had been induced
(Figure 2O). This increase in migration could not be attrib-
uted to an artifact of increased cell proliferation as there was
no change in proliferation using the BrdU incorporation assay
(Figure 2P).
Stable transfection
Since there was no expression of DCC in the MCF-7 cells, as
noted by Miyamoto et al.,45 the relationship between DCC
and other proteins involved in cell migration was studied after
stable transfection with a dcc plasmid as described previously.-
11 The transfected cells appeared normal, with the usual
planar morphology (Figure 3A,a), and were unaffected by
subtilisin at 30 or 100 nM even after 48 h incubation
(Figure 3A,b,c). At the higher concentration of 300 nM sub-
tilisin the cells separated into individuals without forming the
clumps noted in naïve, non-transfected cells (Figure 3A,d;
compare with Figure 2E,f) and individual cells continued to
exhibit a normal morphology suggesting that DCC transfec-
tion had reduced sensitivity to the serine proteases.
The transfection generated clear levels of DCC protein
(Figure 3B) but 6 h incubation with subtilisin at 100 nM did
not reduce expression of this ectopic DCC (Figure 3B) or
neogenin (Figure 3C) compared with DCC in adult rat tissue
and neogenin in untransfected MCF-7 cells. Only at the
higher concentration of 300 nM subtilisin was any loss seen
in DCC or neogenin expression. A similar pattern was
observed for β-catenin expression (Figure 3D), E-cadherin
(Figure 3E) and RhoA (Figure 3F) consistent with a possible
degree of toxicity at 300 nM as noted above. No expression of
vimentin was seen in these cells, as noted above in naïve
MCF-7 cells.
Wound healing assay of cell mobility. To assess the func-
tional effects of DCC transfection, cells were examined in the
wound healing assay of intrinsic mobility. The rate of sponta-
neous migration was lower in the DCC-transfected cells
(P = 0.05) (Figure 3G) consistent with the view that DCC
expression suppresses migration. Chymotrypsin increased the
intrinsic mobility although the effect was smaller in the trans-
fected cells than in naïve cells. Subtilisin at 100 nM increased
migration after DCC transfection consistent with its increased
migratory effect in non-transfected MCF-7 cells.
Spot chemotaxis assay. In the spot chemotaxis assay using
netrin-1 (1000 ng/ml) as the chemoattractant, the resting rate
of migration of transfected cells was significantly greater than
that of naïve cells, but the stimulant effect of netrin was less
than in normal cells and did not reach statistical significance
(Figure 3H). Indeed, the overall number of cells migrating in
response to netrin was significantly less in the transfected cells
(Figure 3H).
Assessment of proliferation. In the BrDU assay of cell pro-
liferation, DCC-transfected cells showed no difference from
naïve cells in the rate of proliferation after 6 h (Figure 3I) or
24 h (Figure 3J) incubation. Neither subtilisin (30 nM or
100 nM) nor chymotrypsin (300 or 1000 nM) affected the
proliferation of MCF-7 cells, normal or transfected (Figure 3I,
J), indicating that changes in cell proliferation were not likely
to have contributed to the changes in apparent cell mobility.
MDA-MB-231 mammary adenocarcinoma cells
Since MCF-7 cells are generally regarded as being relatively
quiescent, we also examined the more aggressive human
breast adenocarcinoma line of MDA-MB-231 cells. MDA-
MB-231 cells are basal type B epithelial cells, indicating their
high level of invasiveness relative to type A.46,47 They are
post-mitotic cells derived from human metastatic
adenocarcinomata,48 with low ability to form intercellular
adhesions.49 They have been reported to express several
EMT markers including vimentin and low levels of differen-
tiated epithelial markers such as E-cadherin.21
In these cells 48 h treatment with chymotrypsin (1 µM)
failed to affect neogenin expression and a high concentration
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Figure 3. Effects of serine proteases on dependence receptor expression in DCC stable-transfected MCF-7 cells.
(A) illustrates cultures of MCF-7 cells after stable transfection with the dcc plasmid. Cultures are shown under control conditions or after 48 hr incubation with
subtilisin (sub) 30, 100 or 300 nM. Only at the highest concentration is there any disruption, with a loss of intercell adhesion but no sign of toxicity or clumping. Scale
bar = 100 μm. (B)-(F) Bar charts showing the quantified Western blot densities of proteins expressed in dcc-transfected MCF-7 cells. Expression is shown of (B) DCC,
(C) neogenin, (D) β-catenin, (E) E-cadherin and (F) RhoA showing the effects of 6 h treatment with chymotrypsin (CT) 300 or 1000 nM and subtilisin (sub) 100 or
300 nM in 10% FBS. Each chart is accompanied by a sample blot. (G) the rate of scratch closure 24 h after wounding cultures under normal control conditions (con) or
in the presence of chymotrypsin 3 μM (CT3) in normal or stably dcc-transfected cells. (H) measurement of cell chemotactic migration to a netrin-1 containing agarose
spot. The chart shows the number of normal or dcc-transfected MCF-7 cells entering the spot over 24 h under control conditions (con) or with the chemotactic
protein netrin-1 (1000 ng/ml) in the spot. Transfected cells showed greater spontaneous movement but were less attracted to the netrin target. (I, J) Comparison of
proliferation rates of normal MCF-7 cells (black columns) and cells transfected with a dcc plasmid (light columns), using the bromodeoxyuridine technique under
control conditions (con) or in the presence of subtilisin (sub) 30 or 100 nM, or chymotrypsin (CT) 300 or 1000 nM. Results are shown after 6 h (I) and 24 h (J). There
were no significant differences in proliferation rate between normal and transfected cells, or between control and protease-treated cultures.
*P < 0.05, **P < 0.01, ***P < 0.001 (n = 3; ANOVA and Bonferroni post hoc test for selected datasets.)
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of 300 nM subtilisin was required to do so in the normal
serum (15%)-containing medium (Figure 4A). In low serum
(1%) medium sensitivity to the proteases was enhanced sub-
stantially, with chymotrypsin (1 μM) and subtilisin even at
100 nM producing over 90% depletion (Figure 4B), changes
qualitatively similar to those seen in MCF-7 cells.
In normal medium, resting MDA-MB-231 cultures consisted
of a mixture of multipolar and spindle-shaped cells (“resting
cells”), together with more spherical cells which had undergone
temporary de-differentiation from the normal phenotype in
preparation for the movement and migration (“active cells”)
which is typical of this line50 (Figure 4C,a). Treatment with
the serine proteases for 48 h increased the proportion of active
profiles (Figure 4C,b–f) at concentrations which reduced neo-
genin expression, but with a good representation of resting cells
even at 300 nM subtilisin (Figure 4,f). This change in profile was
exaggerated in 1% serum medium, in which cells appeared
normal in control medium (Figure 4D,a), but with no resting
profiles visible at 1 μM chymotrypsin (Figure 4D,c) or 100 and
300 nM subtilisin (Figure 4D,e,f).
β-catenin showed quite a different localisation in the
MDA-MB-231 cells (a basal cell-derived line) compared with
that observed above in the luminal epithelium-derived MCF-7
cells (Figure 4E, compare with Figure 2G). The MDA-MB-231
cells showed a more generalised cytoplasmic distribution of
the protein (Figure 4E) compared with the largely peripheral,
membrane-associated localisation in MCF-7 cells. In MDA-
MB-231 cells, β-catenin protein expression was only affected
by subtilisin at 300 nM in normal medium (Figure 4F) but
became more sensitive in low serum, responding to chymo-
trypsin 1 μM and subtilisin 100 nM (Figure 4G). E-cadherin
(Figure 4H,I) and RhoA (Figure 4J,K) showed similar patterns
of changes being unaffected in normal media and becoming
more sensitive in low serum media.
A low level of vimentin expression was observed in naïve
MDA-MB-231 cells (normal 15% medium) (Figure 4L) but, as
in the MCF-7 cells, low serum medium (1%) itself induced a
significant increase in vimentin expression (Figure 4L).
Chymotrypsin (1 μM) and subtilisin (100 nM) inhibited
vimentin expression very significantly in low serum medium.
For an examination of MDA-MB-231 migratory cell beha-
viour in the wound closure assay, cells were cultured in a
medium with reduced serum content (0.1%). This was neces-
sary to suppress spontaneous proliferation to a level which
would not interfere with the assay as MDA-MB-231 cells can
proliferate to close a scratch wound within a few hours,
making it difficult to quantify drug-induced changes on
migration. Subtilisin increased cell migration (Figure 4M)
although the concentrations required (1-3 nM) were lower
than those required in normal media, consistent with the view
expressed above that normal serum contains components
inhibiting the enzyme activity. In the BrdU proliferation
assay neither chymotrypsin nor subtilisin affected prolifera-
tion of the MDA-MB-231 cells in normal medium
(Figure 4N) after a short (2 h) or prolonged (24 h) incubation.
Transient transfection of DCC
To examine the effect of DCC on MDA-MB-231 cell sensitiv-
ity to serine proteases, cells were transiently transfected with
the ectopic dcc plasmid. This generated high levels of the
corresponding protein (Figure 5A) which remained sensitive
to depletion by subtilisin in normal 15% serum medium
(Figure 5A). The expressions of endogenous neogenin
(Figure 5B), β-catenin (Figure 5C) and vimentin (Figure 5D)
were not changed by DCC transfection and these proteins
showed a similar sensitivity to subtilisin in normal and trans-
fected cells. RhoA expression was not affected significantly by
the serine proteases (Figure 5E) with or without transfection.
Primary mammary epithelial cells
To compare normal cells with the transformed lines used
above human primary mammary epithelial cells (HMEpC)
were examined. These cells are maintained in the media
supplied, with no added serum. No DCC was detectable in
these cells, as previously noted by Kenny et al.51 Subtilisin
at 10 nM for 6h was sufficient to reduce substantially the
expression of neogenin (Figure 6A) with no significant
effect on β-catenin (Figure 6B). There was a loss of
vimentin expression (Figure 6C) with 10 nM subtilisin,
and a reduction in N-cadherin with 10 nM subtilisin
(Figure 6D) but no effect on E-cadherin (Figure 6E) or
Rho expression (Figure 6F). These protein changes paral-
leled morphological features of the cells which normally
form monolayer cultures (Figure 6G,a). At 10 nM subtili-
sin, the cultures retain the appearance of single cells or
small groups of loosely adherent cells (Figure 6G,b)
despite the loss of neogenin, β-catenin, vimentin and
N-cadherin but with clear areas appearing devoid of cells
and suggesting possible toxicity on these cells. At 100 nM
subtilisin the cells showed clear signs of damage with
clumping into batches separated by large cell-free areas
(data not shown).
In the wound closure assay, low concentrations of both
chymotrypsin (3 nM) and subtilisin (3 nM) increased the rate
of scratch closure over a 24 h period, indicating an increase in
cell migration (Figure 6H). At the same concentrations there
were no changes in cell proliferation (Figure 6I).
SH-SY5Y cells
The human neuroblastoma line of SH-SY5Y cells was
included as these cells normally have detectable levels of
endogenous DCC. Exposure to subtilisin 300 nM was
required to reduce the expression of DCC (Figure 7A) or
neogenin (Figure 7B), while there was no effect of chymo-
trypsin at 1 µM. Expression of β-catenin (Figure 7C) and
E-cadherin (Figure 7D) were also reduced at 300 nM subtili-
sin while Rho showed a non-significant trend for reduction
(Figure 7E). The serine proteases tended to increase the
expression of vimentin (Figure 7F) with a significant effect
using subtilisin 300 nM, as noted for MCF-7 cells above.
In the wound closure assay of cell migration, incubation
with chymotrypsin at 3 μM or subtilisin at 30 nM for 72 h
increased the rates of cell migration (Figure 7G).
Discussion
DCC and neogenin are ‘dependence receptors’ regulating cell
viability and survival depending on the presence of their
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Figure 4. Effects of serine proteases on dependence receptor expression in MDA-MB-231 cells.
(A, B): Bar charts showing the quantified Western blot densities of proteins expressed in MDA-MB-231 cells. Expression is shown of neogenin after incubation in
normal medium containing the standard 15% FBS (A) or after incubation in low serum (1%) medium (B). The charts indicate expression in normal control cells (con),
or after 48 h exposure to chymotrypsin (CT) 300 or 1000 nM, or subtilisin (sub) 10, 100 or 300 nM. Each chart is accompanied by a sample blot. (C,D) Micrographs of
cultures after exposure to CT 300 or 1000 nM, or subtilisin 30, 100 or 300 nM under control conditions (15% FBS-containing medium) (C) or low serum (1%) medium
(D). Scale bar = 100 μm. (E) immunocytochemical localisation of β-catenin primarily in the cytoplasm. (F-L) show bar charts of quantified Western blot densities for β-
catenin (F, G), E-cadherin (H, I), RhoA (J, K) and vimentin (L) in normal 1%-serum media (F, H, J, L) or after incubation in low serum (1%) media (G, I, K, L). Both high
and low serum data are illustrated together to emphasise the increase in expression induced by low serum (L). The charts indicate expression in normal control cells
(con), or after exposure to chymotrypsin (CT) 300 or 1000 nM, or subtilisin (sub) 30, 100 or 300 nM. Each chart is accompanied by a sample blot. (M) the rate of
scratch closure 24 h after wounding cultures under normal (control) conditions (black column) or in the presence of subtilisin 1 nM (light grey column) or 3 nM (dark
grey column). (N) Measurement of proliferation rate using the bromodeoxyuridine technique under control conditions (con) or in the presence of subtilisin (sub) 30
or 300 nM, or chymotrypsin (CT) 1000 nM. Results are shown after 2 h (black columns) or 24 h (light columns).
*P < 0.05, **P < 0.01, ***P < 0.001 (n = 3; ANOVA and Bonferroni post hoc test for selected datasets.)
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primary ligands, the netrin family of extracellular, secreted
proteins.52,53 DCC has received the most attention since,
compared with normal cells surrounding an early cancerous
growth, the expression of DCC is greatly reduced or absent in
several forms of cancer and genetic changes such as gene
mutation or loss of heterozygosity have been described by
Figure 6. Protein expression in primary human mammary myoepithelial (HMEp) cells.
Bar charts showing the quantified Western blot densities of proteins expressed in primary human mammary myoepithelial (HMEp) cells. Expression is shown of (A)
neogenin, (B) β-catenin, (C) vimentin, (D) N-cadherin, (E) E-cadherin and (F) RhoA. The charts indicate expression in normal control cells (con), or after exposure to
subtilisin (sub) 1, 3 or 10 nM for 6 h. Each chart is accompanied by a sample blot. (G) Micrographs of control cultures (G,a) or after 6 h exposure to subtilisin 10 nM (G,
b). Scale bar = 100 μm.(H) Rate of scratch closure 48 h after wounding control cultures (con) or in the presence of chymotrypsin (CT) 1 or 3 nM, or subtilisin 3 nM. (I)
Measurement of proliferation rate using the bromodeoxyuridine technique under control conditions (con) or in the presence of subtilisin (sub) 3 nM or chymotrypsin
(CT) 3 or 10 nM. Results are shown after 6 h (black columns) or 24 h (light columns).
*P < 0.05, (n = 3; ANOVA and Bonferroni post hoc test for selected datasets.)
Figure 7. Protein expression in SH-SY5Y human neuroblastoma cells.
Bar charts showing the quantified Western blot densities of proteins expressed in SH-SY5Y cells. Expression is shown of (A) DCC, (B) neogenin, (C) β-catenin, (D)
E-cadherin, (E) RhoA and (F) vimentin. The charts indicate expression in normal control cells (con), or after exposure to chymotrypsin (CT) 1 μM or subtilisin (sub) 100
or 300 nM for 48 h. Each chart is accompanied by a sample blot. (G) Rate of scratch closure 48 h after wounding control cultures (con) or in the presence of subtilisin
(sub) 30 nM or chymotrypsin (CT) 3000 nM.
*P < 0.05, (n = 3; ANOVA and Bonferroni post hoc test for selected datasets.)
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many groups.5,26,54–56 Its insertion into cells can inhibit pro-
liferation and migration.3,57–59
The overall functional role of DCC remains elusive, since it
was originally thought to affect proliferation but now appears
to be more relevant to cellular migration, metastasis forma-
tion and chemoresistance.60 Interfering with DCC expression
or function, for example, does not always produce changes in
proliferation or survival.61 However, it has a potentially
important involvement in differentiation.62,63 The protein
was detected in differentiated, mucus-producing cells but
not un-differentiated cells in the intestine and was absent
from colorectal cancer cells which failed to differentiate into
mucus-producing cells.64 These observations are consistent
with the finding that during early development DCC is first
expressed in differentiating neurons65 and that it is required
for the differentiation of neurons induced by Nerve Growth
Factor.4 It is highly expressed in early stage hyperplastic
tissues and then declines in parallel with the extent of meta-
static activity and malignancy.56,63,66 These authors concluded
that DCC expression was associated with maintaining cell
differentiation. A parallel interpretation is that DCC levels
fall, not before or at the beginning of migration, but during
the course of migration and dissemination.5,67 This might
indicate that DCC or neogenin can modulate the transition
of resting cells into the activated, pro-metastatic state of EMT.
Although less well studied, neogenin expression is involved
in cell migration and differentiation in early embryogenesis-
68,69 and is inversely related to tumour activity in several
disorders such as breast cancer.7–9,70–72 The present study
was designed to assess the effects of chymotrypsin and sub-
tilisin on the expression of DCC and neogenin, in parallel
with markers associated with EMT.
EMT represents a major reorganisation of cellular metabo-
lism, a “comprehensive reprogramming” of cell function73
and recent results indicate that EMT may be related to the
development of drug resistance rather than to the promotion
of cell migration.40,60 Furthermore, the deletion of transcrip-
tion factors thought to be essential for EMT, such as Snail and
Twist, did not reduce cancer cell invasiveness or prevent
metastasis.40
We have previously reported that two common serine
proteases, endogenous mammalian chymotrypsin and bacter-
ial subtilisin, reduce the expression of DCC and neogenin at
low physiologically relevant concentrations, accompanied by
increased cell migration.11 The present results confirm this
finding and extend it to several cancer-derived cell lines and
primary human mammary epithelial cells. In most experi-
ments there was selectivity for the depletion of DCC and
neogenin with several other proteins being less affected at
the same protease concentrations.
Inserting dcc increases intercellular adhesion, whereas anti-
sense oligonucleotides increase adhesion to the extracellular
surface.66 This is consistent with our observation that DCC-
transfected cells retain their planar morphology when exposed
to the serine proteases at concentrations which induce cell dis-
sociation of naïve cells. The loss of dependence receptors, espe-
cially inMDA-MB-231 cells, was accompanied by the generation
of increased numbers of separated, isolated, spherical cells.
These have been considered to be invasive, colony-forming
cells74 with high expression of vimentin and N-cadherin but
little or no E-cadherin, a profile typical of cells in EMT.
Cadherin
Under resting conditions most epithelial-derived cells express
high levels of E-cadherin with very low expression of
N-cadherin. E-cadherin is thought to be a major suppressor
of EMT and tumour invasion, EMT being regarded as a
primary marker of normal, non-cancerous, differentiated
cells.16,75,76 A reduction in E-cadherin expression has been
linked with other changes involved in de-differentiation,
oncogenesis and metastasis.20,77,78 There is a moderate expres-
sion in invasive carcinomas without metastases but elevated
levels in metastatic deposits: it is reduced or absent in many
tumours and a decline in expression induces microRNAs
which function as tumour suppressors, limiting invasive,
aggressive behaviour.76,79
Conversely N-cadherin is absent or poorly expressed in
resting cells and its expression rises during EMT. However,
the link between E-cadherin and aggression is not a secure
one, since E-cadherin has been found in all of 69 specimens of
squamous cell carcinomas, more than half of which exhibited
higher than normal levels especially in late stage tumours.19,80
An alternative explanation of our results is that the DCC/
cadherin relationship functions via a non-canonical β-cate-
nin-independent route. Indeed, there are clearly factors affect-
ing E-cadherin expression that remain poorly understood: a
low E-cadherin content has been linked to increased suscept-
ibility of Asian patients to develop colorectal cancer with a
poor prognosis whereas this association does not seem to
apply to European patients.81
The present data are in agreement with the absence of
E-cadherin from MDA-MB-231cells51,82 although it was, as
expected, present in the less invasive MCF-7 cells. Our finding
that serine proteases reduce E-cadherin expression is consis-
tent with a report that trypsin inhibition increased endothelial
E-cadherin levels,83 just as protease inhibition increases DCC
and neogenin expression.11
β-catenin
Cellular concentrations of β-catenin and E-cadherin are
normally complementary, with an increase in β-catenin
expression accompanying a loss of E-cadherin at the start
of EMT or during active periods of migration.34,76,78,84,85
The effect is believed to follow the dissolution of the adhe-
rens junctions, the removal of E-cadherin and the conse-
quent release of bound β-catenin into the cytoplasm:
E-cadherin exerts a stabilising influence on the levels of
β-catenin.16,86–88 Altered expression or activity of β-catenin
has been implicated in regulating proliferation28,84 and
oncogenesis22,33,75,89–91 being proposed as a ‘co-factor’ in
the initiation of EMT.92,93 Inhibition of the Wnt/β-catenin
pathway inhibits cancer cell proliferation31,94,95 although
others have linked β-catenin activation to reduced growth
and increased differentiation.96 The levels of β-catenin
expression may be different in a range of tumour cells
types.25
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β-catenin has already been linked with DCC function.26
Tumours with low DCC levels were found to have reduced
β-catenin expression, leading to the proposal that there might
be some common or mutual regulation of expression.5,27 The
converse pattern is also seen in which induced DCC expres-
sion resulted in a reduction of β-catenin expression in parallel
with effects on proliferation, adhesion and migration.97–99
Several groups have concluded that deletion or interference
with the generation of β-catenin had little overall effect
on cancer-related behaviours such as proliferation or migra-
tion in HCT116 colon cancer cells, although reduced cell
adhesion was noted.100 This may explain why β-catenin levels
can appear to be independent of cell proliferation and
migration.
The present results reveal β-catenin expression in cells in
the virtual absence of DCC, and also show that levels were
reduced by the serine proteases (consistent with26) not
increased as expected for cells with increased mobility.
Although subtilisin and CT remove DCC and neogenin
from cells, increasing cell migration, they reduce rather than
promote the expression of β-catenin and vimentin, leading to
the conclusion that the sequence of events they induce is not
directly related to the EMT and may represent either a non-
canonical equivalent process or a completely independent
mechanism for increased migration. Indeed, both β-catenin
and E-cadherin may have several functions within the cell
unrelated to carcinogenesis including tissue regeneration101
and it is possible that changes in their expression induced
by serine proteases have a greater effect on some of those
alternative activities than on those directly related to
oncogenesis.
A different perspective is that the loss of β-catenin and
DCC exhibit a distinct but important difference in pharma-
cology. The loss of β-catenin is prevented by both PIC and
chymostatin whereas only the latter compound prevents the
removal of DCC and neogenin. Not only does this mean that
slight differences exist in the relevant target site protein
structure but, more importantly, it indicates that the loss of
β-catenin and DCC are very unlikely to be sequential in a
common pathway. If there were close functional links, target-
ing the more distal site in the pathway should affect the
cellular function or expression of both proteins.
MCF-7 cells show good levels of β-catenin in the mem-
brane and cytoplasm after stimulation by Wnt ligands, but not
in the nucleus.102 Since these authors found β-catenin in
cytoplasmic endosomes, Golgi bodies and coated complexes,
they suggested that these might reflect cellular functions of
β-catenin unrelated to oncogenesis, such as Golgi body trans-
port. If correct, this could explain some of the inconsistencies
of β-catenin behaviour and the possibility that in some situa-
tions the balance of functions might give rise to an overall
decrease in β-catenin expression, rather than an increase.
These observations are consistent with the suggestion that
β-catenin might have other functions in the cell independent
of any role in proliferation or migration.84 This might also
account for our finding good levels of β-catenin expression in
tumour cells where there is no DCC.
In the absence of DCC, netrin drives cells into EMT,
proliferation and migration.24,85,103,104 In early embryonic
development, netrin induces a decrease in DCC expression
which results in new cell formation and migration to form the
developing organs and tissues in mammals and Drosophila.105
The reported ability of netrin to induce E-cadherin degrada-
tion leading to EMT and cell migration85 might be related to
this early loss of DCC. The over-expression of netrins in some
human cancers106,107 may then be driving tumour formation
via the down-regulation of DCC and E-cadherin expression
resulting in destabilisation of the differentiated state and the
promotion of oncogenesis.
Vimentin
The intermediate filament protein vimentin is the major
cytoskeletal protein in mesenchymal cells and has become
one of the most widely used markers of EMT21 correlating
with the relatively aggressive proliferative and migratory
activity of cells during embryogenesis and cancer
metastasis.36–38,79,108–110 In the absence of vimentin, migra-
tion is significantly reduced.39 Thus the E-cadherin/vimen-
tin ratio determines the switch from low to high invasion
capacity. It has been proposed that a major regulator of
EMT – Transforming Growth Factor-β – is responsible for
the induction of vimentin expression and the decrease in
E-cadherin.111
Independent changes in the expression of β-catenin and
vimentin have been reported by others. For example, vimen-
tin can be increased in the absence of any changes in
β-catenin112 and Messi et al113 have described aggressively
invasive cells which do not possess vimentin. We have
observed here that vimentin expression increases when cells
are incubated in low serum media, consistent with the report
of differentiation being accompanied by an increase
in vimentin.114 However, the increased expression of vimentin
by chymotrypsin and subtilisin may be sufficient to explain
the protease-induced increase of migration in the absence of
the normally associated increase of β-catenin, perhaps imply-
ing its ability to promote motility without EMT.
Future avenues
An important aspect of any research conclusion is the recog-
nition that it can apply with certainty only to the experimental
preparations used and there may be a different spectrum of
factors operating in other systems. While information from
such alternative systems cannot invalidate the existing data, it
may throw further light on the interpretation of results and
their general applicability and may yield new insights based
on the variations of results obtained in relation to fundamen-
tal differences in the biology and behaviour of those systems.
In this respect, the differences in rates of cell proliferation,
migration and tissue invasiveness between cell types and their
origins should allow the functional significance of different
results to be used to improve substantially the hypotheses that
have been pursued here.
An outstanding example might be the use of primary
human glioblastoma cells which exhibit atypically high
rates of migration and infiltration accounting for the high
mortality associated with them.115 These cells, as primary
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cells, do not carry some of the inevitable limitations of
studying cell lines which are, by their nature, already trans-
formed and often passaged for an unclearly defined number
of times. Another reason for studying glioblastoma cells is
that proteases have been clearly linked with their migration
and invasive potential, although these have been identified
as primarily cysteine proteases, such as cathepsins B and
S115-117 which are likely to have actions and targets quite
different from those of the serine proteases which are the
focus of the present work. Nevertheless, future work on
aggressive cancer cells of this and similar origins could
prove highly informative in the context of the present
results.
Conclusions
There are two overall conclusions from this work. Firstly, the
relationship between β-catenin, cadherins and vimentin appears
to depend on the cell type, culture medium and whether the cells
are resting or challenged with serine proteases. β-catenin expres-
sion parallels the serine protease-induced changes in the depen-
dence receptors, although with reduced sensitivity. There is no
clear or consistent relationship between several of the proteins
thought to be associated with EMT, so the concept that EMT can
be characterised by a fall in E-cadherin expression coupled with
an increase in vimentin, β-catenin and N-cadherin does not
entirely account for the increased cell migration induced by
serine proteases. This might then imply that a range of cell
properties could be reflected in the quantitative, possibly quali-
tative and, most importantly, relative changes in EMT-related
protein expression.
Secondly, however, E-cadherin expression is reduced by
the proteases and vimentin expression is increased, consistent
with conventional views of EMT and leading to the conclu-
sion that among the EMT marker proteins, differential
changes can be induced by some treatments such as serine
proteases. The events induced by these enzymes may repre-
sent either a non-canonical equivalent process to EMT or an
independent mechanism for increased migration. More work
on these relationships is clearly needed.
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